Author’s response to reviews

Title: Cost-effectiveness analysis of pneumococcal conjugate vaccine 13-valent in older adults in Colombia

Authors:

Jaime E Ordóñez (jordonez@une.net.co)
John J Orozco (jjorozco@miune.net)

Version: 2 Date: 13 August 2013

Author’s response to reviews:

Mrs.: Philippa Harris
Executive Editor
BMC Infectious Diseases

We want to introduce our paper titled "Cost-effectiveness analysis of pneumococcal 13-valent conjugate vaccine in older adults in Colombia" and explain you why we believe it should be published in this important journal. Our study is an economic evaluation of pneumococcal vaccination in older adults, and therefore, there are two aspects about it that are related to BMC Infectious Diseases.

First, this is the evaluation of a vaccine to prevent pneumococcal disease, and this kind of diseases is one of the targets in this journal. In fact, BMC Infectious Diseases has published several articles on various aspects about pneumococcal disease in both children and older adults.

The other aspect that is important to note, is that our study goes beyond evaluating the clinical efficacy and it evaluates cost-effectiveness of these technologies, generating useful information for decision makers, that is useful to develop health policies to prevent pneumococcal diseases that can benefit not only people with risk factors but also to general population.

We hope you find interesting our paper and we have the honor to be published in BMC Infectious Diseases.

Sincerely yours.